The effects of montelukast sodium in conjunction with budesonide/formoterol on pulmonary function and serum markers (interleukin-6, tumor necrosis factor-a, eosinophils (EOS) count) in obstructive airway diseases (asthma and chronic obstructive pulmo

Montelukast sodium in conjunction with budesonide/formoterol presents a pronounced advantage in effectiveness and safety for treating obstructive airway diseases in individuals. It effectively alleviates symptoms, enhances pulmonary function, and diminishes inflammation, offering critical insights for clinical management.